The Utility of NIOM During LITT for Refractory MTLE

首次发布于 2016 年 9 月 26 日

Electrophysiological Biomarkers in MTLE Patients.

计划入组 1 人 · 首次发布于 2021 年 1 月 14 日

MRgLITT for mTLE: A PROBE Trial

计划入组 120 人 · 首次发布于 2024 年 12 月 6 日

oligonucleotide therapy (refractory gout)

GMC-1

allogenic NK cell therapy (refractory myelodysplastic syndrome)

Actinium

United States

Scynexis

United States

NeuroPace

United States

uniQure Doses First Patient in Phase I/IIa Trial of AMT-260 for Refractory Mesial Temporal Lobe Epilepsy

uniQure Doses First Patient in Phase I/IIa Trial of AMT-260 for Refractory Mesial Temporal Lobe Epilepsy

uniQure's Gene Therapy AMT-260 Achieves 92% Seizure Reduction in First Drug-Resistant Epilepsy Patient